Anika Therapeutics, Inc. (ANIK)
NASDAQ: ANIK · IEX Real-Time Price · USD
25.84
+0.41 (1.61%)
Apr 19, 2024, 4:00 PM EDT - Market closed
Anika Therapeutics Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Anika Therapeutics stock have an average target of 29.5, with a low estimate of 22 and a high estimate of 37. The average target predicts an increase of 14.16% from the current stock price of 25.84.
Analyst Consensus: Buy
* Price targets were last updated on Mar 14, 2024.
Analyst Ratings
The average analyst rating for ANIK stock from 2 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Nov '23 | Dec '23 | Jan '24 | Feb '24 | Mar '24 | Apr '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 2 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Barrington Research | Barrington Research | Buy Maintains $29 → $37 | Buy | Maintains | $29 → $37 | +43.19% | Mar 14, 2024 |
| Stephens & Co. | Stephens & Co. | Hold Reiterates $22 | Hold | Reiterates | $22 | -14.86% | Mar 14, 2024 |
| Barrington Research | Barrington Research | Buy Maintains $28 → $29 | Buy | Maintains | $28 → $29 | +12.23% | Jan 3, 2024 |
| Barrington Research | Barrington Research | Buy Maintains $24 → $28 | Buy | Maintains | $24 → $28 | +8.36% | Nov 3, 2023 |
| Barrington Research | Barrington Research | Hold → Buy Upgrades $24 | Hold → Buy | Upgrades | $24 | -7.12% | Aug 14, 2023 |
Financial Forecast
Revenue This Year
173.82M
from 166.66M
Increased by 4.29%
Revenue Next Year
182.83M
from 173.82M
Increased by 5.18%
EPS This Year
0.01
from -5.64
EPS Next Year
-0.05
from 0.01
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 179.6M | 188.3M | 206.2M | 255.5M | 282.2M |
| Avg | 173.8M | 182.8M | 197.7M | 248.2M | 274.2M |
| Low | 166.4M | 175.6M | 187.5M | 238.4M | 263.4M |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 7.7% | 8.3% | 12.8% | 29.2% | 13.7% |
| Avg | 4.3% | 5.2% | 8.1% | 25.5% | 10.5% |
| Low | -0.1% | 1.0% | 2.5% | 20.6% | 6.1% |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 0.22 | 0.35 | 0.56 | 0.63 | 0.87 |
| Avg | 0.01 | -0.05 | 0.38 | 0.61 | 0.85 |
| Low | -0.20 | -0.46 | 0.22 | 0.59 | 0.81 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | 6,694.1% | - | 64.7% | 42.4% |
| Avg | - | - | - | 60.0% | 38.3% |
| Low | - | - | - | 53.7% | 32.9% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.